Navigation Links
Study Shows Increased Out-of-Pocket Expenses May Negatively Influence Initiation of TNF Blocker Therapy
Date:4/21/2008

Prime Therapeutics to present findings at AMCP Conference in April

ST. PAUL, Minn., April 21 /PRNewswire/ -- Prime Therapeutics (Prime), a thought leader in pharmacy benefit management, today announced the results of its study, "Association Between Tumor Necrosis Factor (TNF) Blocker Out-of-Pocket (OOP) Expense and Member Decline to Fill Rate". The study assessed the association between decline-to-fill rates as they relate to out-of-pocket expense for members initiating TNF-blocker therapy for the treatment of inflammatory conditions such as rheumatoid arthritis. The use of TNF blocker agents to treat rheumatoid arthritis has been increasing among the aging U.S. population and treatment for the disease is becoming more and more costly.(1)

Because of Prime's close working relationship with many large health plans, Prime is uniquely positioned to analyze both pharmaceutical and medical data to closely monitor drug safety, effectiveness, costs and prescribing practices. Through the evaluation of pharmacy claims of 4.4 million members from four major Blue Cross and Blue Shield Plans between July 2006 and June 2007, Prime was able to determine that members with an out-of-pocket cost greater than $250 were 4.6 times more likely to decline to fill their initial TNF-blocker medication.

In determining this, Prime found that more than six of seven members initiating TNF-blocker therapy had a per-claim, out-of-pocket expense of $100 or less with a low decline to fill rate of one in 50. The study also found that this decline to fill rate increased to at least one out of every 10 members when the out-of-pocket expense was $251 to $500 and grew to one out of every 5 when members paid the entire cost of greater than $1000. Members generally need to pay approximately $250 when they have a 20% coinsurance pharmacy benefit and they would have to pay the entire cost early in the year when their pharmacy benefit is a consumer directed healthcare product. '/>"/>

SOURCE Prime Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014 Becker's Healthcare is excited ... Program on October 23-25, 2014 at the Swissotel ... - The Business and Operations of ASCs brings ... continuing education, networking events, and an exhibit hall ... Outstanding educational offerings throughout the three-day event, The ...
(Date:9/2/2014)... BOSTON (September 2, 2014 4 pm EDT): In a ... American Medical Association , a team of Boston researchers ... improve dietary quality in the United States. The researchers ... at Tufts University, Harvard University and Boston Children,s Hospital ... subsidizing healthier foods could both help people make meaningful ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Cloud Medical ... of “Cloud Based” Medical Practice Business Operations solutions and ... of Digital Cyber Security solutions for all industries announced ... on the trading floor of the CME in Chicago ... DeLaGarza stated that we are very proud of the ...
(Date:9/2/2014)... by radiation therapy survived as long as patients ... study conducted by researchers at the Stanford University ... of California. , The comprehensive analysis of nearly ... first to directly compare survival rates following the ... removal of both breasts), unilateral mastectomy (the removal ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Medex ... location of their corporate headquarters in Coral Springs, Fla. ... have exceeded our business development objectives for the 2014 ... Neil Herbst. “Our industry has requested a higher level ... utilization reviews. Medex has delivered, and the industry has ...
Breaking Medicine News(10 mins):Health News:Becker's Healthcare Announces Ambulatory Surgery Center Educational Program 2Health News:Becker's Healthcare Announces Ambulatory Surgery Center Educational Program 3Health News:Taxes and subsidies could encourage healthier diet and lower healthcare costs 2Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 2Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 3Health News:Breast cancer patients with bilateral mastectomy don't have better survival rates 2Health News:Breast cancer patients with bilateral mastectomy don't have better survival rates 3Health News:Breast cancer patients with bilateral mastectomy don't have better survival rates 4Health News:Medex Analytic Services Announces New Location for Corporate Headquarters 2
... Nov. 25 Thanksgiving meals will be delivered to approximately ... to Faith In Action/Volunteer Action for Aging, a program operated ... Plan. For more than 17 years these organizations have gathered ... in need in Long Beach, Lakewood, Signal Hill, South Bay, ...
... LOS ANGELES, Nov. 25 The Black AIDS Institute recently ... 2010. , The new Board Members are a highly diverse ... government health programs, editorial, and business entrepreneurship. The Board also ... heterosexual and gay Black men and women, some living with ...
... Broad Political Endorsements, Business, and Press Join Effort to ... again, the National Bipolar Foundation and the MedicAlert Foundation receive ... now being widely accepted as a preventive health care measure ... proclamation of endorsement via Federal Express Priority Mail from the ...
... have found evidence of a statistically significant survival ... receptor (ER)-positive tumors had high levels of phosphorylation ... a brief communication published online November 25 in ... . Approximately 50% of breast carcinomas are ...
... pressure? This simple question has been the focus of ... High Blood Pressure in Mice & Men, Does stress increase ... of intense research for many years. Now new research ... novel gene, phosducin, and the blood pressure response to stress ...
... Rituximab, already used to fight rheumatoid arthritis, could help ... (HealthDay News) -- A drug commonly used to treat ... promise in helping patients newly diagnosed with type 1 ... producing some of their own insulin, even though the ...
Cached Medicine News:Health News:SCAN Employees and Community Volunteers to Help Deliver One Thousand Thanksgiving Meals to Homebound Seniors 2Health News:Black AIDS Institute Announces 2010 Board Election Results 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 3Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 4Health News:New stress-related gene modulates high blood pressure in mice and men 2Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3
(Date:9/2/2014)... , Sept. 2, 2014  On July 31, ... to Congress that it is moving forward to regulate ... the minutes until laboratories throughout the U.S. will need ... Although some medical laboratories may subscribe to the ... FDA to put guidelines in place, it,s widely acknowledged ...
(Date:9/2/2014)... 2, 2014  Reportlinker.com announces that a new market ... Chinese and Taiwanese Markets for Minimally Invasive Spinal ... The market for MIS spinal devices in ... is growing at a fast pace, albeit at different ... happening in China , where MIS ...
(Date:9/2/2014)... The Pharmaceutical Care Management Association (PCMA), the ... filed a lawsuit in Iowa ... law that restricts tools used by PBMs ... and consumers.  The law—HF 2297—forces PBMs ... use of Maximum Allowable Cost (MAC) lists that keep ...
Breaking Medicine Technology:FDA Tells Congress It Intends to Regulate LDTs! Web Conference to Provide Straight Talk on Essential Steps Clinical Laboratories and Pathology Groups Will Need to Take to Comply 2FDA Tells Congress It Intends to Regulate LDTs! Web Conference to Provide Straight Talk on Essential Steps Clinical Laboratories and Pathology Groups Will Need to Take to Comply 3Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 2Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 3Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 4Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 5Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 6Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 7Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 8Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 9Lawsuit Challenges Iowa Health Mandate that Forces Employers to Pay More for Prescription Drugs 2
... Double-Blind Study Targets Biomarker-Defined Population, BERKELEY ... GNTA ) announced that the first ... Phase 3 trial of Genasense,(oblimersen sodium) Injection ... is a randomized, double-blind, placebo-controlled study in ...
... Editor-in-Chief of New Brain Stimulation Journal, CHARLESTON, ... (MUSC) today announced the results of a functional ... Nerve Stimulation) Therapy(TM),for patients with treatment-resistant depression (TRD). ... MUSC Department of Psychiatry,appears in the August 2007 ...
Cached Medicine Technology:Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 2Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 3Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 4Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 5New Study Supports Efficacy of Vagus Nerve Stimulation for Treatment-Resistant Depression 2New Study Supports Efficacy of Vagus Nerve Stimulation for Treatment-Resistant Depression 3
Blunt tipped forceps with small, slightly rounded tips angled perpendicular to the shaft. For grasping peripheral membranes....
... As a pioneer in the design and ... extraction of viscous fluids, D.O.R.C. is pleased ... combination of injection and extraction in one ... controlled injection of viscous fluids, such as ...
... both 96- and 384-well plates and ... Washer. As a self contained and ... full control of precise fluidic delivery ... simple squeeze bottle to the full ...
The EL401 Manual Plate/Strip Washer accommodates all 96-well microplates and microwell strips. The unique alignment mechanism allows quick and accurate positioning of the 8- or 12-channel manifold ab...
Medicine Products: